| 101 |
NCT00002947 |
Terminated |
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer |
- Brain and Central Nervous System Tumors
- Childhood Langerhans Cell Histiocytosis
- Gastrointestinal Carcinoid Tumor
- (and 9 more...)
|
- Radiation: indium In 111 pentetreotide
|
Interventional |
Phase 1 |
- Yale University
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
35 |
All |
18 Years and older (Adult, Senior) |
NCT00002947 |
CDR0000065414
YALE-HIC-9041
NCI-G97-1154 |
|
October 1996 |
August 2004 |
August 2004 |
March 26, 2004 |
July 2, 2014 |
|
- Yale Comprehensive Cancer Center
New Haven, Connecticut, United States
|
| 102 |
NCT02727686 |
Recruiting |
Post-Operative Water Load Following Transsphenoidal Pituitary Surgery |
- Hyponatremia
- Pituitary Adenoma
|
- Other: Water Load (WL) Post-Operative Day 1
|
Interventional |
Not Applicable |
- St. Joseph's Hospital and Medical Center, Phoenix
- Barrow Brain and Spine
- Barrow Neurological Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- POD1 Response Serum Sodium
- POD1 Response Serum Osmolality
- POD1 Response Urine Output
- (and 2 more...)
|
15 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02727686 |
PHX1600103012 |
|
April 2016 |
December 2017 |
January 2018 |
April 5, 2016 |
October 12, 2016 |
|
- Barrow Brain and Spine
Phoenix, Arizona, United States
|
| 103 |
NCT02803697 |
Recruiting |
Predictive Factors of Recurrence of Non Functioning Pituitary Adenomas : a Retrospective Study of 220 Patients in the Reims University Hospital, France |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Recurrence rate / predictive factors of recurrence
|
220 |
All |
18 Years and older (Adult, Senior) |
NCT02803697 |
PA13045 |
|
November 2015 |
March 2017 |
November 2017 |
June 17, 2016 |
December 28, 2016 |
|
- Chu de Reims
Reims, France
|
| 104 |
NCT00383708 |
Completed |
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients |
|
- Drug: lanreotide (Autogel formulation)
- Drug: Pegvisomant
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The percentage of acromegalic patients with normalised (age and sex adjusted) IGF-1 level at the end of the co-treatment period.
- Acromegaly symptoms
- Quality of life
- (and 9 more...)
|
125 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00383708 |
2-55-52030-727 |
|
October 2006 |
October 2008 |
October 2008 |
October 3, 2006 |
June 19, 2012 |
|
- University Hospital, Charles University
Hradec Kralove, Czech Republic - Charles University
Prague, Czech Republic - Aarhus Kommunehospital
Aarhus, Denmark - (and 21 more...)
|
| 105 |
NCT02574793 |
Completed |
Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects |
|
- Device: continuous glucose monitoring
|
Observational |
|
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Continuous glucose profiles of mean data of 24-hour continuous glucose monitoring by the CGMS Gold
- The mean amplitude of glycemic excursion of newly diagnosed GH adenoma patients
- The mean amplitude of glycemic excursion of newly diagnosed Cushing Syndrome patients during the 3 days monitored by CGMS Gold
- (and 2 more...)
|
60 |
All |
Child, Adult, Senior |
NCT02574793 |
KY2015-152 |
|
December 1, 2014 |
December 31, 2017 |
January 7, 2018 |
October 14, 2015 |
January 23, 2018 |
|
- Xiaolong Zhao
Jing'an, Shanghai, China
|
| 106 |
NCT02834013 |
Recruiting |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
- Acinar Cell Carcinoma
- Adenoid Cystic Carcinoma
- Adrenal Cortex Carcinoma
- (and 82 more...)
|
- Procedure: Biospecimen Collection
- Biological: Ipilimumab
- Biological: Nivolumab
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR) defined as confirmed and unconfirmed complete and partial response
- Incidence of adverse events graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Best response calculated from the sequence of RECIST 1.1 and immune-related response criteria (irRC) objectives
- (and 3 more...)
|
707 |
All |
18 Years and older (Adult, Senior) |
NCT02834013 |
NCI-2016-01041
S1609
U10CA180888 |
|
January 13, 2017 |
August 31, 2020 |
|
July 15, 2016 |
April 24, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 815 more...)
|
| 107 |
NCT00973557 |
Completed |
The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function |
- Colorectal Cancer
- Lung Cancer
- Breast Cancer
- Glioblastoma
|
|
Observational |
|
- Cedars-Sinai Medical Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- To determine whether the drug, Bevacizumab (a monoclonal anti VEGF-A antibody), which is approved to treat patients with metastatic colon cancer induces hyperprolactinemia (increased prolactin secretion) in humans with intact pituitary function.
|
6 |
All |
18 Years and older (Adult, Senior) |
NCT00973557 |
Pro00019830 |
|
September 2009 |
September 2011 |
January 2012 |
September 9, 2009 |
February 7, 2012 |
|
- Cedars-Sinai Medical Center
Los Angeles, California, United States
|
| 108 |
NCT02160730 |
Recruiting |
Treatment of Cushing's Disease With R-roscovitine |
|
|
Interventional |
Phase 2 |
- Shlomo Melmed, MD
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Cedars-Sinai Medical Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with a normalized 24 hour urinary free cortisol after 4 weeks
- Change in levels of pituitary hormones
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- (and 4 more...)
|
16 |
All |
18 Years and older (Adult, Senior) |
NCT02160730 |
Pro35720
1R21DK103198-01 |
|
May 2014 |
December 2018 |
December 2019 |
June 11, 2014 |
January 29, 2018 |
|
- Cedars-Sinai Medical Center
Los Angeles, California, United States
|
| 109 |
NCT03382158 |
Recruiting |
International PPB Registry for PPB, DICER1 and Associated Conditions |
- Pleuropulmonary Blastoma
- Sertoli-Leydig Cell Tumor
- DICER1 Syndrome
- (and 10 more...)
|
|
Observational |
|
- Children's Hospitals and Clinics of Minnesota
- Children's Research Institute
- Washington University School of Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Event-free survival
- Overall response to chemotherapy
- Overall survival
- (and 4 more...)
|
100 |
All |
Child, Adult, Senior |
NCT03382158 |
FDAAA |
|
December 6, 2016 |
December 6, 2023 |
December 6, 2026 |
December 22, 2017 |
December 22, 2017 |
|
- Children;s Minnesota
Minneapolis, Minnesota, United States
|
| 110 |
NCT02484755 |
Unknown † |
Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease |
- Cushing's Disease
- Corticotrophin Adenoma
|
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in levels of 24 hour urinary free cortisol after 4 weeks
- Number of participants with a normalized 24 hour urinary free cortisol after 4 weeks
- Change in levels of Late-Night Salivary Cortisol after 4 weeks
- (and 4 more...)
|
6 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02484755 |
KY2015-167 |
|
June 2015 |
September 2015 |
|
June 30, 2015 |
June 30, 2015 |
|
- Huashan Hospital
Shanghai, Shanghai, China
|
| 111 |
NCT02536261 |
Recruiting |
Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus |
- Invasive Prolactinomas Involving the Cavernous Sinus
|
|
Observational |
|
- Zhebao Wu
- Xinqiao Hospital of Chongqing
- First Hospital of China Medical University
- (and 6 more...)
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Change from baseline on PRL level
- Change from baseline on tumor volume measured by enhanced pituitary Magnetic Resonance Imaging（MRI）
- Change from baseline of visual acuity
- Change from baseline on 5 point visual field scale
|
30 |
All |
15 Years to 70 Years (Child, Adult, Senior) |
NCT02536261 |
WSIP-1586 |
|
June 2016 |
December 2019 |
|
August 31, 2015 |
May 16, 2017 |
|
- Beijing Tiantan Hospital
Beijing, Beijing, China - Peking Union Medical College Hospital
Beijing, Beijing, China - Xinqiao Hospital of Chongqing
Chongqing, Chongqing, China - (and 5 more...)
|
| 112 |
NCT01444209 |
Recruiting |
Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas |
|
- Radiation: Iodine Implants
|
Interventional |
Phase 2 |
- University of Texas Southwestern Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Partial response (reduction in 30% of tumor volume) or greater response within 12 months from the implant procedure.
- Change of the patient's Humphrey visual field testing
- Potential toxicities associated with interstitial seed placement
- (and 3 more...)
|
24 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT01444209 |
STU 042011-075 |
|
October 2011 |
December 2017 |
December 2020 |
September 30, 2011 |
January 9, 2017 |
|
- University of Texas Southwestern Medical Center
Dallas, Texas, United States
|
| 113 |
NCT02233335 |
Completed |
The Factors Associated With the Recurrence in Patients With Cushing Disease |
|
|
Observational |
|
- National Taiwan University Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Number of participants with disease persistence or recurrence after surgery, which was determined by clinical symptoms, biochemical lab, dynamic test and image study
|
42 |
All |
Child, Adult, Senior |
NCT02233335 |
201305026RINC |
|
June 2013 |
May 2014 |
May 2014 |
September 8, 2014 |
September 8, 2014 |
|
- National Taiwan University Hospital
Taipei, Taiwan
|
| 114 |
NCT03364803 |
Recruiting |
Collecting Information About Treatment Results for Patients With Cushing's Syndrome |
- Cushing's Disease
- Cushing Syndrome
- Cushing Disease
|
- Other: Cushing's QoL (Quality of Life Questionnaire)
- Other: Nottingham Health Profile (NHP)
- Other: Hospital Anxiety and Depression Scale (HADS)
- (and 8 more...)
|
Observational |
|
- Memorial Sloan Kettering Cancer Center
- Memorial Sloan Kettering Cancer Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Collection of data on Cushing's Syndrome participants before and over time after surgical, medication, and/or radiation therapy.
|
200 |
All |
14 Years and older (Child, Adult, Senior) |
NCT03364803 |
17-592 |
|
November 28, 2017 |
November 28, 2024 |
November 28, 2024 |
December 7, 2017 |
March 15, 2018 |
|
- Memorial Sloan - Kettering Cancer Center
New York, New York, United States
|
| 115 |
NCT03400865 |
Not yet recruiting |
Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas |
- Resistance, Disease
- Prolactinoma
|
- Drug: HCQ/CQ and CAB combined treatment
|
Interventional |
Not Applicable |
- Zhebao Wu
- Xinqiao Hospital of Chongqing
- First Hospital of China Medical University
- (and 7 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline on prolactin(PRL) level
- Change from baseline on tumor volume measured by enhanced pituitary Magnetic Resonance Imaging（MRI）
- Change from baseline of visual acuity
- Change from baseline on 5 point visual field scale
|
30 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03400865 |
HCCT-2018 |
|
February 25, 2018 |
December 30, 2020 |
December 30, 2020 |
January 17, 2018 |
January 17, 2018 |
|
- Beijing Tiantan Hospital
Beijing, Beijing, China - Huashan Hospital
Shanghai, Shanghai, China - Ruijin Hosipital
Shanghai, Shanghai, China - (and 6 more...)
|
| 116 |
NCT02637479 |
Recruiting |
Treatment of Opioid-refractory Pain (WHO Level III) by Pituitary Radiosurgery |
- Any Cancer With Multiple Bone Metastases
|
- Device: GammaKnife®
- Device: 18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)
- Device: MRI
|
Interventional |
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The pain assessment
- assessment of the visual fields
- assessment of the visual acuity
- (and 4 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02637479 |
2014-51
2015-A00616-43
RCAPHM15_0022 |
Hyporadoul |
December 2015 |
December 2018 |
December 2018 |
December 22, 2015 |
December 22, 2015 |
|
- Assistance Publique Hôpitaux de Marseille
Marseille, France
|
| 117 |
NCT01143584 |
Unknown † |
Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. |
|
- Drug: Cabergoline
- Drug: cabergoline
|
Interventional |
Not Applicable |
- Postgraduate Institute of Medical Education and Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Normoprolactinemia
- Duration for resolution of Hypogonadism
|
20 |
All |
Child, Adult, Senior |
NCT01143584 |
prlcab2020 |
|
May 2010 |
December 2011 |
March 2012 |
June 14, 2010 |
June 14, 2010 |
|
- Postgraduate Institute of Medical Education and Research
Chandigarh, India
|
| 118 |
NCT03038308 |
Recruiting |
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole |
- Hyperprolactinemia
- Prolactinoma
|
|
Interventional |
Phase 1
Phase 2 |
- Columbia University
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Prolactin concentrations
- Tumor size
|
26 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03038308 |
AAAI8604
1R21DK112093-01 |
|
September 16, 2016 |
July 1, 2019 |
July 1, 2019 |
January 31, 2017 |
January 31, 2017 |
|
- Columbia University Medical Center
New York, New York, United States
|
| 119 |
NCT02310269 |
Recruiting |
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease |
|
|
Observational |
|
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Observational Model: Other
- Time Perspective: Prospective
|
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability profile of pasireotide s.c.
- The proportion of patients that reach mean UFC ≤ ULN as short and long-term efficacy measure
- Changes of mean UFC measures of disease activity
- (and 20 more...)
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02310269 |
CSOM230B2410 |
|
March 28, 2013 |
May 14, 2024 |
May 14, 2024 |
December 8, 2014 |
March 6, 2018 |
|
- Massachusetts General Hospital SC - SOM230B2410
Boston, Massachusetts, United States - Ohio State University SC - SOM230B2410
Columbus, Ohio, United States - Allegheny Endocrinology Associates
Pittsburgh, Pennsylvania, United States - (and 45 more...)
|
| 120 |
NCT02350153 |
Active, not recruiting |
Cushing´s Disease Epidemiology in Sweden |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Mortality
- influence of Cushing's Disease on myocardial infarction
- influence of Cushing's Disease on stroke
- (and 4 more...)
|
400 |
All |
18 Years and older (Adult, Senior) |
NCT02350153 |
NSSCDIO |
|
September 2013 |
May 2018 |
September 2018 |
January 29, 2015 |
August 24, 2017 |
|
- Sahlgrenska University Hospital
Gothenburg, Vastra Gotaland Region, Sweden
|
| 121 |
NCT02697734 |
Recruiting |
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease |
|
- Drug: osilodrostat
- Drug: osilodrostat Placebo
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percentage of randomized participants with a complete response
- Percentage of participants with mUFC ≤ ULN
- Percentage of patients with complete response mUFC ≤ ULN and partial response with mUFC decrease ≥ 50% from baseline and > ULN)
- (and 7 more...)
|
69 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02697734 |
CLCI699C2302 |
LINC-4 |
October 3, 2016 |
October 25, 2019 |
October 25, 2019 |
March 3, 2016 |
November 14, 2017 |
|
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States - Washington University School of Medicine
Saint Louis, Missouri, United States - Columbia University Medical Center- New York Presbyterian Neuroendocrine Unit
New York, New York, United States - (and 29 more...)
|
| 122 |
NCT03297892 |
Not yet recruiting |
Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015 |
|
|
Observational |
|
- University Hospital, Brest
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rates de remission and recurrence after the first surgery
- predictive factors of remission and recurrence
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT03297892 |
CUSHING RB (15.217) |
CUSHING |
October 2017 |
March 2018 |
March 2018 |
September 29, 2017 |
October 5, 2017 |
|
|
| 123 |
NCT00434148 |
Completed
Has Results |
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease |
|
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Group
- Change From Baseline in mUFC
- Time to First UFC Response
- (and 12 more...)
|
162 |
All |
18 Years and older (Adult, Senior) |
NCT00434148 |
CSOM230B2305
2006-004111-22 |
|
December 2006 |
March 2010 |
May 2014 |
February 12, 2007 |
March 8, 2016 |
February 6, 2013 |
- Stanford University Medical Center Stanford Cancer Center (3)
Stanford, California, United States - University Chicago Hospital Dept. of Univ of Chicago
Chicago, Illinois, United States - Dana Farber Cancer Institute The Melanoma Program
Boston, Massachusetts, United States - (and 65 more...)
|
| 124 |
NCT02568982 |
Recruiting |
Cushing's Disease Complications |
|
- Other: Exams and questionnaires
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- number of complications (hormonal and imaging results, quality of life) per patient (composite)
- Remission rate of Cushing's disease
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT02568982 |
P120132 |
COMPLICUSHING |
September 21, 2015 |
March 2020 |
September 2020 |
October 6, 2015 |
March 19, 2018 |
|
- AP-HP, Hôpital Cochin
Paris, France
|
| 125 |
NCT02180217 |
Active, not recruiting |
Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease |
|
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of randomized patients in each arm with mUFC ≤ ULN
- Proportion of enrolled patients with mUFC ≤ ULN at Week 24
- Time-to-last control of mUFC
- (and 11 more...)
|
137 |
All |
18 Years and older (Adult, Senior) |
NCT02180217 |
CLCI699C2301
2013-004766-34 |
|
October 6, 2014 |
March 23, 2018 |
December 7, 2018 |
July 2, 2014 |
October 18, 2017 |
|
- University of Colorado Hospital SC - LCI699C2301
Aurora, Colorado, United States - Emory University School of Medicine/Winship Cancer Institute G2304 - C2301
Atlanta, Georgia, United States - Northwestern University SC - LCI699C2301
Chicago, Illinois, United States - (and 64 more...)
|
| 126 |
NCT03353025 |
Recruiting |
Study on Therapy of Non-invasive Prolactinoma |
|
- Procedure: transsphenoidal surgery treatment
- Drug: dopamine agonist treatment
|
Interventional |
Not Applicable |
- First Affiliated Hospital, Sun Yat-Sen University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
394 |
All |
18 Years to 60 Years (Adult) |
NCT03353025 |
2016008 |
TNAPA |
January 1, 2016 |
December 31, 2025 |
December 31, 2025 |
November 24, 2017 |
November 24, 2017 |
|
- Sun Yat-sen 5010 program
Guangzhou, China
|
| 127 |
NCT03080181 |
Completed |
Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment |
|
- Drug: Pasireotide 0.6 MG/ML
|
Interventional |
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change of circulating adipokines levels
- Change of homeostasis model assessment (HOMA-β )
- Change of area under the curve (AUC2h) of C-peptide during a mixed meal tolerance test
- Change of M value evaluated by the euglycemic hyperinsulinemic clamp
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT03080181 |
Pasireotide-CD |
|
May 2013 |
December 30, 2016 |
January 28, 2017 |
March 15, 2017 |
October 27, 2017 |
|
|
| 128 |
NCT03111810 |
Recruiting |
Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition |
- Iatrogenic Cushing's Disease
|
- Drug: AZD4017 and prednisolone
- Drug: Placebo Oral Tablet and prednisolone
|
Interventional |
Phase 2 |
- University of Oxford
- AstraZeneca
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Changes in the detrimental side effects of prednisolone by AZD4017.
- Changes in hepatic insulin sensitivity by AZD4017 when given with prednisolone (20mg) compared to prednisolone (20mg) given alone.
- Changes in blood pressure associated with prednisolone and AZD4017 administration
- (and 7 more...)
|
32 |
Male |
18 Years to 60 Years (Adult) |
NCT03111810 |
212634 |
TICSI |
May 25, 2017 |
December 2018 |
January 2019 |
April 13, 2017 |
October 6, 2017 |
|
- University of Oxford
Oxford, United Kingdom
|
| 129 |
NCT01374906 |
Completed
Has Results |
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease |
|
- Drug: pasireotide LAR
- Drug: SOM230 LAR 30 mg
- Drug: SOM230 LAR 10 mg
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage Participants That Attained a mUFC ≤ 1.0 x ULN at Month 7 Regardless of Dose Titration
- Percentage of Participants That Attained a mUFC ≤ 1.0 x ULN at Month 7 and Had Not Had a Dose Increase at Month 4
- Actual Change in Mean Urinary Free Cortisol (mUFC) From Baseline
- (and 26 more...)
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT01374906 |
CSOM230G2304
2009-011128-70 |
|
November 4, 2011 |
December 21, 2016 |
December 21, 2016 |
June 16, 2011 |
April 11, 2018 |
April 11, 2018 |
- ClinTriCo
Phoenix, Arizona, United States - University of California at Los Angeles UCLA Tiverton
Los Angeles, California, United States - Harbor-UCLA Medical Center LA Biomed
Torrance, California, United States - (and 78 more...)
|
| 130 |
NCT02603653 |
Unknown † |
Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease |
|
- Device: Virtual radial task in 3D
|
Interventional |
Not Applicable |
- Institut National de la Santé Et de la Recherche Médicale, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Percentage of right answers at virtual radial task in 3D
- General Quality of life
- Specific Quality of life for Cushing's Disease
- (and 4 more...)
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT02603653 |
C15-02
IDRCB |
MEMOCUSH |
November 2015 |
May 2016 |
May 2017 |
November 13, 2015 |
November 13, 2015 |
|
- Hôpital du Haut-Lévêque
Pessac, France
|
| 131 |
NCT00521300 |
Completed |
Preoperative Octreotide Treatment of Acromegaly |
|
- Drug: Octreotide
- Procedure: Direct surgery for acromegaly
|
Interventional |
Phase 4 |
- St. Olavs Hospital
- Novartis
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Surgical cure by transsphenoidal surgery
- Effect of treatment on surgical complications and duration of hospital stay, pituitary function, quality of life, and the need for postsurgical medical treatment of acromegaly
|
62 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00521300 |
S-71-98 (REK)
S-71-98
SLKNR 98-5560 |
POTA |
September 1999 |
June 2005 |
May 2010 |
August 27, 2007 |
June 2, 2014 |
|
- Endocrinology Unit, Department of Medicine, Haukeland University Hospital
Bergen, Norway - Endocrinology Unit, Department of Medicine, Aker University Hospital
Oslo, Norway - Endocrinology Unit, Department of Medicine, Rikshospitalet-Radiumhospitalet Medical Center
Oslo, Norway - (and 2 more...)
|
| 132 |
NCT01925092 |
Withdrawn |
Mifepristone in Children With Refractory Cushing's Disease |
|
|
Interventional |
Phase 3 |
- Corcept Therapeutics
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
0 |
All |
6 Years to 17 Years (Child) |
NCT01925092 |
13-CH-0170
02811-12 |
|
August 2013 |
December 2016 |
|
August 19, 2013 |
August 4, 2014 |
|
- National Institute of Child Health and Human Development (NICHD)
Bethesda, Maryland, United States
|
| 133 |
NCT01331239 |
Active, not recruiting |
Safety and Efficacy of LCI699 in Cushing's Disease Patients. |
|
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in 24 hour urine free cortisol concentration
- Changes on steroid hormones of the HPA-axis in plasma, urine and saliva
- Changes in metabolic abnormalities, e.g. insulin, Hemoglobin A1C (HbA1C)
- Safety and tolerability of multiple doses of LCI699
|
33 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01331239 |
CLCI699C2201
2010-022403-22 |
|
March 23, 2011 |
December 21, 2018 |
December 21, 2018 |
April 8, 2011 |
October 16, 2017 |
|
- Northwestern University Endo, Metabolism and Molecular
Chicago, Illinois, United States - Massachusetts General Hospital Neuroendocrine Unit
Boston, Massachusetts, United States - Cleveland Clinic Foundation
Cleveland, Ohio, United States - (and 8 more...)
|
| 134 |
NCT02060383 |
Recruiting |
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly |
- Cushing's Disease
- Acromegaly
|
- Drug: Pasireotide s.c.
- Drug: Sitagliptin
- Drug: Liraglutide
- (and 3 more...)
|
Interventional |
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Change in HbA1c from randomization to approximately 16 weeks
- Change in HbA1c and FPG (Fasting Plasma Glucose) from randomization over time and to Core EOP (End of Phase) (only for FPG) per randomized arm
- Proportion of patients who required anti-diabetic rescue therapy with insulin in the incretin based arm
- (and 4 more...)
|
246 |
All |
18 Years and older (Adult, Senior) |
NCT02060383 |
CSOM230B2219
2012-002916-16 |
|
May 23, 2014 |
April 13, 2018 |
April 13, 2018 |
February 12, 2014 |
February 2, 2018 |
|
- Diabetes and Endocrine Associates La Mesa Location
Multiple Locations, California, United States - LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219
Torrance, California, United States - Coastal Metabolic Research Centre SC
Ventura, California, United States - (and 44 more...)
|
| 135 |
NCT00088608 |
Completed |
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease |
|
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Urinary Free Cortisol after 15 days of treatment
- Serum cortisol
- ACTH
- (and 5 more...)
|
26 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00088608 |
CSOM230B2208 |
|
April 2004 |
June 2006 |
|
August 2, 2004 |
November 7, 2016 |
|
- Cedars-Sinai Pituitary Center
Los Angeles, California, United States - Massachusetts General Hospital NE Unit
Boston, Massachusetts, United States - Oregon Health & Science University
Portland, Oregon, United States - (and 2 more...)
|
| 136 |
NCT01371565 |
Completed
Has Results |
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome |
- Cushing's Disease
- Cushing's Syndrome
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events
|
4 |
All |
18 Years and older (Adult, Senior) |
NCT01371565 |
C1073-405 |
|
November 2010 |
June 2012 |
September 2012 |
June 13, 2011 |
March 18, 2014 |
November 20, 2013 |
- The Center for Diabetes and Endocrine Care
Hollywood, Florida, United States - Sinai Hospital of Baltimore
Baltimore, Maryland, United States - University of Michigan Medical Center
Ann Arbor, Michigan, United States - (and 2 more...)
|
| 137 |
NCT02081768 |
Recruiting |
90Yttrium Colloid for the Treatment of Cystic Sellar/Parasellar Tumors |
- Cystic Tumors of the Sellar/Parasellar Region
|
- Radiation: 90yttrium colloid
|
Interventional |
Phase 3 |
- David Clarke
- Nova Scotia Health Authority
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cyst shrinkage
- Localization of intracystic 90yttrium colloid by PET-CT
|
40 |
All |
17 Years and older (Child, Adult, Senior) |
NCT02081768 |
Yttrium2014 |
|
June 2014 |
June 2024 |
June 2025 |
March 7, 2014 |
April 20, 2017 |
|
- Halifax Infirmary
Halifax, Nova Scotia, Canada
|
| 138 |
NCT00460616 |
Completed |
Cardiac Valve Complications in Prolactinomas Treated With Cabergoline |
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Prevalence of regurgitation (graded as mild, moderate, severe) at any cardiac valve.
|
50 |
All |
18 Years to 65 Years (Adult) |
NCT00460616 |
NeuroendoUnit-2 |
ValveCab |
January 2007 |
|
September 2007 |
April 16, 2007 |
April 16, 2008 |
|
- Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples
via S. Pansini 5 Naples, Italy
|
| 139 |
NCT00697814 |
Completed |
Clomiphene in Males With Prolactinomas and Persistent Hypogonadism |
- Hypogonadotropic Hypogonadism
- Prolactinoma
|
|
Interventional |
Phase 2 |
- Federal University of São Paulo
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
|
- assess the effects of CC treatment on testosterone levels in male patients with prolactinomas and persistent HH on dopaminergic agonist therapy
- Assess the effects of CC on sexual function, fertility, body composition, lipid and glucose metabolism, and quality of life were also evaluated.
|
15 |
Male |
18 Years to 70 Years (Adult, Senior) |
NCT00697814 |
1374/04 |
|
June 2004 |
June 2005 |
June 2005 |
June 16, 2008 |
June 16, 2008 |
|
- Neuroendocrine Unit - Escola Paulista de Medicina (UNIFESP)
Sao Paulo, SP, Brazil
|
| 140 |
NCT00881283 |
Terminated |
Long-term Cardiovascular Risk in Cured Cushing's Patients |
|
|
Observational |
|
- Massachusetts General Hospital
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
|
1 |
Female |
35 Years to 55 Years (Adult) |
NCT00881283 |
2008-p-001379 |
|
September 8, 2008 |
March 30, 2010 |
March 30, 2010 |
April 15, 2009 |
January 20, 2017 |
|
- Neuroendocrine Clinical Center
Boston, Massachusetts, United States
|
| 141 |
NCT00171951 |
Completed |
Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease |
|
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Long term efficacy (UFC) in patients with Cushing's disease
- Long term safety
- Tolerability
- (and 2 more...)
|
19 |
All |
18 Years and older (Adult, Senior) |
NCT00171951 |
CSOM230B2208E1
2004-002407-32 |
|
August 2004 |
July 2013 |
July 2013 |
September 15, 2005 |
November 16, 2016 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Oregon Health & Sciences University Dept.ofOregonHealth&SciencesU.
Portland, Oregon, United States - University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States - (and 5 more...)
|
| 142 |
NCT00845351 |
Unknown † |
Preoperative Bexarotene Treatment for Cushing's Disease |
|
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- diurnal plasma ACTH
- cortisol levels
- Adverse events
- clinical outcomes
|
6 |
All |
18 Years to 65 Years (Adult) |
NCT00845351 |
13936 |
|
November 2008 |
December 2011 |
December 2011 |
February 18, 2009 |
May 30, 2011 |
|
- University of Virginia
Charlottesville, Virginia, United States
|
| 143 |
NCT00481299 |
Completed |
Insulin Resistance in Women With Prolactinoma |
- Prolactinoma
- Insulin Resistance
- Hyperlipidemia
|
|
Observational |
|
- Universidade Federal do Rio de Janeiro
|
Other |
- Observational Model: Defined Population
- Primary Purpose: Screening
- Time Perspective: Cross-Sectional
- Time Perspective: Prospective
|
|
2004 |
Female |
18 Years to 48 Years (Adult) |
NCT00481299 |
178/04 |
|
October 2004 |
|
September 2006 |
June 1, 2007 |
June 1, 2007 |
|
- Clementino Fraga Filho University Hospital
Rio de Janeiro, RJ, Brazil
|
| 144 |
NCT00081341 |
Completed |
Cognition, Steroids, and Imaging in Cushings Disease |
|
|
Observational |
|
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
NIH |
- Time Perspective: Prospective
|
|
|
All |
9 Years and older (Child, Adult, Senior) |
NCT00081341 |
51337DK (completed) |
|
|
|
December 2002 |
April 12, 2004 |
February 15, 2010 |
|
- General Clinical Research Center, University of Michigan Health System
Ann Arbor, Michigan, United States
|
| 145 |
NCT02792582 |
Recruiting |
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection |
|
- Radiation: Proton Therapy
- Procedure: Surgery
|
Interventional |
Phase 2 |
- St. Jude Children's Research Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Overall survival (OS)
- Compare incidence of first cystic intervention with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital
- (and 3 more...)
|
140 |
All |
up to 21 Years (Child, Adult) |
NCT02792582 |
RT3CR
NCI-2016-00813 |
|
June 22, 2016 |
June 2025 |
June 2027 |
June 7, 2016 |
September 28, 2017 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
| 146 |
NCT00934271 |
Completed |
Fractionated Stereotactic Radiotherapy in Patients With Acromegaly |
|
- Radiation: fractionated stereotactic radiotherapy
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Tumour control by pituitary MRI
- biochemical remission
- Affection of other pituitary axes
- withdrawal of somatostatin analogue and growth hormone receptor antagomist
|
34 |
All |
18 Years and older (Adult, Senior) |
NCT00934271 |
FSRT-SR-UFR |
|
January 2002 |
January 2008 |
January 2008 |
July 8, 2009 |
October 28, 2014 |
|
- National University Hospital, Department of Medical Endocrinology
Copenhagen, Denmark
|
| 147 |
NCT03348501 |
Recruiting |
Study and Follow-up of Multiple Endocrine Neoplasia Type 1 |
- Multiple Endocrine Neoplasia
|
- Other: survey for long-term follow-up of the disease
|
Observational |
|
- Centre Hospitalier Universitaire Dijon
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Questionnaire or Life quality
|
2000 |
All |
Child, Adult, Senior |
NCT03348501 |
GOUDET PARI2011 |
GENEM |
July 2012 |
July 2031 |
July 2031 |
November 21, 2017 |
November 21, 2017 |
|
- CHU Dijon Bourgogne
Dijon, France
|
| 148 |
NCT03137615 |
Completed |
The Cardiovascular Changes Associated With Septal Local Anaesthesia |
- Hypothalamic Neoplasms
- Pituitary Diseases
- Anesthesia, Local
|
- Procedure: Pituitary surgery
- Drug: local anaesthetic injection
|
Observational |
|
- Sheffield Teaching Hospitals NHS Foundation Trust
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Change in blood pressure after administration of local anaesthesia
- Change in heart rate after administration of local anaesthesia
- Change in cardiac output after administration of local anaesthesia
- Change in systemic vascular resistance after administration of local anaesthesia
|
15 |
All |
17 Years and older (Child, Adult, Senior) |
NCT03137615 |
STH17059 |
|
November 2014 |
June 2015 |
June 2015 |
May 3, 2017 |
May 3, 2017 |
|
|
| 149 |
NCT01403324 |
Terminated |
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer |
|
|
Interventional |
Not Applicable |
- Gustave Roussy, Cancer Campus, Grand Paris
- Gustave Roussy, Cancer Campus, Grand Paris
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- the 124 I uptake after TSH stimulation
- The activity of 131I that should be administered according to each TSH stimulation method
- Radiation exposure of the blood
|
4 |
All |
18 Years and older (Adult, Senior) |
NCT01403324 |
DOSIMETA IGR2010/1645 |
DOSIMETA |
September 2011 |
June 2016 |
June 2016 |
July 27, 2011 |
July 13, 2016 |
|
- Institut Gustave Roussy
Villejuif, France
|
| 150 |
NCT03262129 |
Recruiting |
Type 1 Multiple Endocrine Neoplasia Cohort Study |
- Type 1-Multiple Endocrine Neoplasia Syndrome
|
|
Observational |
|
- Centre Hospitalier Universitaire Dijon
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Vital status
- MEN-1 related tumors
|
2000 |
All |
Child, Adult, Senior |
NCT03262129 |
GOUDET PARI 2011 |
MEN1-GTEcohort |
January 1, 2012 |
January 2020 |
December 2020 |
August 25, 2017 |
August 25, 2017 |
|
- Chu Dijon Bourgogne
Dijon, France
|
Create an RSS feed from your search for:
Download the search results for: